在疫苗供应有限的情况下，优先为癌症患者接种 COVID-19 疫苗。
Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited.
机构信息
Department of Medicine and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California.
American Association for Cancer Research, Philadelphia, Pennsylvania.
出版信息
Cancer Discov. 2021 Feb;11(2):233-236. doi: 10.1158/2159-8290.CD-20-1817. Epub 2020 Dec 19.
Abstract
Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination.
摘要
已发表的关于 COVID-19 的系列研究支持这样一种观点，即癌症患者是一个特别脆弱的群体。癌症和 COVID-19 之间存在风险因素的交集，癌症治疗和治疗会增加接触病毒的机会，并可能抑制自然免疫反应。现有证据支持这样的结论，即癌症患者，特别是血液系统恶性肿瘤患者，应被视为 COVID-19 疫苗接种的极高危人群之一。
相似文献
1
Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited.在疫苗供应有限的情况下，优先为癌症患者接种 COVID-19 疫苗。
Cancer Discov. 2021 Feb;11(2):233-236. doi: 10.1158/2159-8290.CD-20-1817. Epub 2020 Dec 19.
2
Priority allocation of pandemic influenza vaccines in Australia - Recommendations of 3 community juries.澳大利亚大流行性流感疫苗的优先分配 - 3 个社区陪审团的建议。
Vaccine. 2021 Jan 8;39(2):255-262. doi: 10.1016/j.vaccine.2020.12.010. Epub 2020 Dec 13.
3
[The vaccines are here: Are we ready?].疫苗来了：我们准备好了吗？
Biomedica. 2021 Mar 19;41(1):5-7. doi: 10.7705/biomedica.6072.
4
Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection.血液恶性肿瘤患者 COVID-19 两剂疫苗系列的免疫原性：三例突破性感染报告。
Cancer Control. 2022 Jan-Dec;29:10732748211070720. doi: 10.1177/10732748211070720.
5
SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies.SARS-CoV-2 疫苗在血液系统恶性肿瘤患者中诱导的体液和细胞免疫。
Semin Hematol. 2022 Oct;59(4):192-197. doi: 10.1053/j.seminhematol.2022.11.001. Epub 2022 Nov 19.
6
Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者 COVID-19 疫苗失败的原因和后果。
Eur J Haematol. 2022 Feb;108(2):91-98. doi: 10.1111/ejh.13722. Epub 2021 Dec 5.
7
A Reserve System for the Equitable Allocation of a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.一种严重急性呼吸综合征冠状病毒2疫苗公平分配的储备系统。
Chest. 2021 Mar;159(3):1292-1293. doi: 10.1016/j.chest.2020.08.2042. Epub 2021 Jan 14.
8
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.与实体癌患者相比，血液系统恶性肿瘤患者在第三次接种新冠疫苗后的免疫反应有所降低。
Cancer Cell. 2022 Feb 14;40(2):114-116. doi: 10.1016/j.ccell.2021.12.013. Epub 2021 Dec 29.
9
COVID-19 in Patients with Hematologic Malignancies: Outcomes and Options for Treatments.COVID-19 于血液系统恶性肿瘤患者：结局与治疗选择。
Acta Haematol. 2022;145(3):244-256. doi: 10.1159/000522436. Epub 2022 Feb 8.
10
Rationing of Civilian Coronavirus Disease 2019 Vaccines While Supplies Are Limited.2019年新型冠状病毒病疫苗在供应有限时的分配
J Infect Dis. 2020 Nov 9;222(11):1776-1779. doi: 10.1093/infdis/jiaa569.
引用本文的文献
1
The Influence of Radioligand Therapy on Immunogenicity Against SARS-CoV-2-A Retrospective Single-Arm Cohort Study of Metastatic Prostate Cancer Patients Receiving PSMA Radioligand Therapy.放射性配体疗法对针对严重急性呼吸综合征冠状病毒2免疫原性的影响——一项接受前列腺特异性膜抗原放射性配体疗法的转移性前列腺癌患者的回顾性单臂队列研究
Cancers (Basel). 2025 Jun 2;17(11):1865. doi: 10.3390/cancers17111865.
2
Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial.癌症患者中COVID-19 mRNA疫苗的预测生物标志物和特异性免疫反应：CACOV-VAC试验的前瞻性结果
BMJ Oncol. 2023 Dec 14;2(1):e000054. doi: 10.1136/bmjonc-2023-000054. eCollection 2023.
3
Is COVID-19 Vaccination Beneficial for Tumor Patients: A Cross-Sectional Investigation in China.新冠病毒疫苗接种对肿瘤患者有益吗？来自中国的一项横断面研究。
Immun Inflamm Dis. 2024 Nov;12(11):e70069. doi: 10.1002/iid3.70069.
4
Prognostic model for gastric cancer patients with COVID-19 and network pharmacology study on treatment by lentinan.COVID-19 相关胃癌患者预后模型及香菇多糖治疗的网络药理学研究
Sci Rep. 2024 Oct 20;14(1):24645. doi: 10.1038/s41598-024-76783-2.
5
Low booster uptake in cancer patients despite health benefits.尽管有健康益处，但癌症患者的加强针接种率较低。
iScience. 2024 Jul 26;27(9):110596. doi: 10.1016/j.isci.2024.110596. eCollection 2024 Sep 20.
6
mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy.mRNA-1273 疫苗接种可诱导接受免疫治疗和/或化疗的实体瘤患者产生多功能记忆 CD4 和 CD8 T 细胞应答。
Front Immunol. 2024 Aug 27;15:1447555. doi: 10.3389/fimmu.2024.1447555. eCollection 2024.
7
Association between prostate cancer and susceptibility, hospitalization, and severity of COVID-19: Based on a Mendelian randomization study.基于孟德尔随机化研究的前列腺癌与 COVID-19 易感性、住院和严重程度的相关性。
Medicine (Baltimore). 2024 Sep 6;103(36):e39430. doi: 10.1097/MD.0000000000039430.
8
Increased Risk of Breakthrough SARS-CoV-2 Infections in Patients with Colorectal Cancer: A Population-Based Propensity-Matched Analysis.结直肠癌患者中出现SARS-CoV-2突破性感染的风险增加：一项基于人群的倾向匹配分析。
J Clin Med. 2024 Apr 24;13(9):2495. doi: 10.3390/jcm13092495.
9
Survival and safety analysis of COVID-19 vaccine in Chinese patients with non-small cell lung cancer.新型冠状病毒肺炎疫苗在中国非小细胞肺癌患者中的生存及安全性分析
Cancer Med. 2024 Apr;13(8):e7032. doi: 10.1002/cam4.7032.
10
Age, Gender, and Liver Enzyme Impact Hospital Stay in COVID-19 Minority Patient with Cancer in the USA: Does Race Matters in the Pandemic?年龄、性别和肝酶对美国新冠肺炎合并癌症的少数族裔患者住院时间的影响：种族在疫情中起作用吗？
Ann Clin Med Case Rep. 2024;13. Epub 2024 Mar 21.
本文引用的文献
1
COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers.纽约市多发性骨髓瘤患者的新冠病毒感染情况及临床结局：一项来自五个学术中心的队列研究
Blood Cancer Discov. 2020 Jul 30;1(3):234-243. doi: 10.1158/2643-3230.BCD-20-0102. eCollection 2020 Nov.
2
Cancer History and Systemic Anti-Cancer Therapy Independently Predict COVID-19 Mortality: A UK Tertiary Hospital Experience.癌症病史和全身抗癌治疗独立预测 COVID-19 死亡率：英国一家三级医院的经验
Front Oncol. 2020 Nov 20;10:595804. doi: 10.3389/fonc.2020.595804. eCollection 2020.
3
The Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020.免疫实践咨询委员会关于分配 COVID-19 疫苗初始供应的临时建议-美国，2020 年。
MMWR Morb Mortal Wkly Rep. 2020 Dec 11;69(49):1857-1859. doi: 10.15585/mmwr.mm6949e1.
4
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
5
Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection.美国癌症和 COVID-19 感染患者的风险、种族差异和结局分析。
JAMA Oncol. 2021 Feb 1;7(2):220-227. doi: 10.1001/jamaoncol.2020.6178.
6
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.SARS-CoV-2 mRNA-1273疫苗接种后反应的持久性。
N Engl J Med. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3.
7
When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities.当血液系统恶性肿瘤在美国遭遇 COVID-19：感染、死亡和差异。
Blood Rev. 2021 May;47:100775. doi: 10.1016/j.blre.2020.100775. Epub 2020 Nov 9.
8
COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry.癌症患者中的 COVID-19：临床特征和结局——LEOSS 登记处的分析。
Ann Hematol. 2021 Feb;100(2):383-393. doi: 10.1007/s00277-020-04328-4. Epub 2020 Nov 7.
9
Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis.COVID-19 感染癌症患者的临床特征和结局：系统评价和荟萃分析。
J Natl Cancer Inst. 2021 Apr 6;113(4):371-380. doi: 10.1093/jnci/djaa168.
10
Multivariate mortality analyses in COVID-19: Comparing patients with cancer and patients without cancer in Louisiana.多变量 COVID-19 死亡率分析：比较路易斯安那州的癌症患者和非癌症患者。
Cancer. 2021 Jan 15;127(2):266-274. doi: 10.1002/cncr.33243. Epub 2020 Oct 28.
Zotero 插件